ArticleInternational journal of general medicine2025
Banxia Gualou Xiebai Tang and Qishen Yiqi Dropping Pills Combined Therapy for Qi Deficiency, Phlegm, and Blood Stasis Syndrome in Post-PCI Coronary Heart Disease Patients.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effects of Banxia Gualou Xiebai Tang combined with Qishen Yiqi Dropping Pills on Qi deficiency, phlegm, and blood stasis syndrome in post-percutaneous coronary intervention (PCI) coronary heart disease (CHD) patients. Methods: A retrospective analysis was conducted on 100 post-PCI CHD patients with Qi deficiency, phlegm, and blood stasis syndrome treated from October 2022 to April 2024. Patients were divided into a control group (n=50, receiving standard secondary prevention) and an observation group (n=50, receiving additional Banxia Gualou Xiebai Tang and Qishen Yiqi Dropping Pills). Treatment efficacy, TCM syndrome scores, cardiac function (LVEF, LVEDD, LVESD, CO), blood lipids (TC, TG, HDL-C, LDL-C), hemorheological parameters (PV, Hct, HSBV, LSBV), and adverse events were compared. Results: ① The total effective rate in the observation group (92.0%) was significantly higher than in the control group (76.0%) (P<0.05). ② TCM syndrome scores significantly improved in both groups, with greater improvement in the observation group at 3 and 6 months (P<0.05). ③ Cardiac function: LVEF and CO increased, while LVEDD and LVESD decreased in both groups, with more significant changes in the observation group (P<0.05). ④ Blood lipids: TC, TG, and LDL-C decreased, and HDL-C increased in both groups, with greater changes in the observation group (P<0.05). ⑤ Hemorheology: PV, Hct, HSBV, and LSBV decreased more in the observation group (P<0.05). ⑥ Adverse events: The observation group had a higher incidence of adverse events (22.0% vs 14.0%, P<0.05). Conclusion: Banxia Gualou Xiebai Tang combined with Qishen Yiqi Dropping Pills, alongside standard treatment, significantly improves efficacy, cardiac function, hemorheology, and blood lipids in post-PCI CHD patients without increasing adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.